Medtronic, Inc. (MDT) recently launched a new product, M-Link cellular accessory, which enables cardiac device patients with an option to securely send information stored in their implanted devices to their clinics via the CareLink Network using cellular signals, rather than a telephone landline. This enables clinicians to monitor more patients from a remote location.
The new M-Link cellular accessory enables patients to stay connected with their clinic from home, work or while traveling and results in a fewer in-clinic visits. Physicians and nurses can view the transmitted data through a secure web site at real time.
The Medtronic CareLink Network is the world’s largest and most widely used remote monitoring system for implantable cardiac device patients. More than 4,000 clinics and 500,000 patients in 30 countries have already been enrolled with Medtronic’s CareLink Network.
It has been tested in Medtronic’s CONNECT (Clinical Evaluation of Remote Notification to Reduce Time to Clinical Decision) study that patients implanted with cardiac resynchronization therapy-defibrillator (CRT-D) or implantable cardioverter-defibrillator (ICD) and monitored through the CareLink Network experienced a significant decline in time from clinical event to clinical decision. They were also benefited from shorter hospital stays and reduced hospitalization costs.
We think that the new product will be highly accepted by physicians and nurses due to their enhanced features. This will in turn expand Medtronic’s top-line.
Medtronic is one of the world’s leading medical technology companies, specializing in implantable and interventional therapy devices and products. The company’s major rivals are Boston Scientific Corp. (BSX) and St. Jude Medical, Inc. (STJ).
Currently, we have a ‘Neutral’ recommendation on Medtronic.
Read the full analyst report on “MDT”
Read the full analyst report on “BSX”
Read the full analyst report on “STJ”
Zacks Investment Research
